Harrow Health IncChange company Symbol lookupSelect an option...HROW Harrow Health IncMSFT Microsoft CorpOMGA Omega Therapeutics IncINBS Intelligent Bio Solutions IncPAYX Paychex IncPYR Pyrogenesis Canada IncPM Philip Morris International IncGWAV Greenwave Technology Solutions IncSLNO Soleno Therapeutics IncVRPX Virpax Pharmaceuticals IncGo
Harrow Health, Inc. is an eyecare pharmaceutical company. The Company is focused on the discovery, development, and commercialization of ophthalmic therapies. The Company serves ophthalmologists and optometrists by providing branded ophthalmic pharmaceuticals and compounded prescription medicines. The Company's specializes in the development, production, sale and distribution of prescription medications that serve unmet needs in the marketplace through its subsidiaries and deconsolidated companies. The Company owns the United States commercial rights to approximately 10 branded ophthalmic pharmaceutical products, including IHEEZO, IOPIDINE (both approved concentrations), MAXITROL eye drops, MOXEZA, ILEVRO, NEVANAC, VIGAMOX, MAXIDEX, and TRIESENCE. The Company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business, and its branded drugs are marketed under its Harrow name.
|
|
|
|
| |
Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.